Decades long research led by Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes, the milestone marks a new dawn of treatment options for more than 1.5 million people – and other diseases.
The FDA has approved the SetPoint System, a groundbreaking implantable vagus nerve implant device offering a new treatment approach for rheumatoid arthritis. Developed from decades of research by Kevin J. Tracey, MD, at the Feinstein Institutes for Medical Research, the device stimulates the vagus nerve, a major communication pathway in the body.